A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours by Penson, R T et al.
A phase I clinical trial of continual alternating etoposide and
topotecan in refractory solid tumours
RT Penson*,1, MV Seiden
1, UA Matulonis
2,3, LJ Appleman






1 and JP Eder Jr
3
1Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA;
2Brigham and Women’s
Hospital Division of Gynecologic Oncology, Boston, MA 02114, USA;
3Dana-Farber Cancer Institute and Division of Adult Oncology, Department of
Medicine and the Dana Farber/Harvard Cancer Center, Boston, MA 02114, USA;
4Department of Gynecology and Obstetrics, Massachusetts General
Hospital, Boston, MA 02114, USA
The goal of this phase I study was to develop a novel schedule using oral etoposide and infusional topotecan as a continually
alternating schedule with potentially optimal reciprocal induction of the nontarget topoisomerase. The initial etoposide dose was
15mgm
 2 b.i.d. days (D)1–5 weeks 1,3,5,7,9 and 11, escalated 5mg per dose per dose level (DL). Topotecan in weeks 2,4,6,8,10
and 12 was administered by 96h infusion at an initial dose of 0.2mgm
 2day
 1 with a dose escalation of 0.1, then at
0.05mgm
 2day
 1. Eligibility criteria required no organ dysfunction. Two dose reductions or delays were allowed. A total of 36
patients with a median age of 57 (22–78) years, received a median 8 (2–19) weeks of chemotherapy. At DL 6, dose-limiting
toxicities consisted of grade 3 nausea, vomiting and intolerable fatigue. Three patients developed a line-related thrombosis or
infection and one subsequently developed AML. There was no febrile neutropenia. There were six radiologically confirmed
responses (18%) and 56% of patients demonstrated a response or stable disease, typically with only modest toxicity. Oral etoposide
35mgm
 2 b.i.d. D1–5 and 1.8mgm
 2 96h (total dose) infusional topotecan D8–11 can be administered on an alternating continual
weekly schedule for at least 12 weeks, with promising clinical activity.
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Etoposide and topotecan are both schedule-dependent cytotoxics
that have a broad spectrum of antineoplastic activity. Both interact
with topoisomerases, essential nuclear enzymes that cleave DNA
to reduce torsional strain during replication and recombination.
Topotecan interacts with topoisomerase I (topo I), inducing
reversible single-stranded breaks and a compensatory upregula-
tion in topoisomerase II (topo II). (Liu, 1989) Etoposide binds to
topo II to cause double-stranded DNA breaks with a compensatory
increase in topo I. This see-saw compensation occurs with a delay
such that sequential treatment may offer the optimal schedule of
treatment. (Eder et al, 1998) Continual exposure to schedule-
dependent cytotoxics was first shown to be effective for acute
lymphocytic leukaemia of childhood and since then, the investiga-
tion of protracted exposure to such agents has been the centre of
much of the investigation of the pharmacodynamics of che-
motherapy. (Furman et al, 1976; Collins et al, 1990). With the
positive experience of sequencing the two topoisomerase interac-
ting agents, doxorubicin and topotecan (Seiden et al, 2002), this
study was conceived, building on the anticipation that continual
exposure may maximise the benefit of repeatedly alternating
topoisomerase I and II interacting drugs, and to define the
maximum-tolerated dose (MTD).
DNA topoisomerases are nuclear enzymes essential for DNA
replication, RNA transcription, chromosomal condensation and
mitotic chromatid separation (Caron and Wang, 1993; Gupta et al,
1995; Kohn and Pommier, 2000). There are two major classes of
topoisomerases, I and II, in eukaryotic cells. Topoisomerase I
relaxes DNA by forming a covalent bond with the 30-terminus of a
DNA nucleotide, producing a single-stranded break (Gupta et al,
1995). Topoisomerase II functions as a dimer and forms a double-
stranded cleavage with each topoisomerase II molecule covalently
bound to the 50-terminus of a DNA nucleotide, producing a
double-stranded break (Holm et al, 1985). Topoisomerase-targeted
agents stabilise a transient covalent enzyme–DNA complex, which
produces DNA strand cleavage and apoptosis (Kohn and Pommier,
2000). Preclinical study of the in vivo therapeutic effect of
sequential combinations of topoisomerase I- and II-acting drugs
in a murine tumour model system reveals that topoisomerase I
mRNA and protein levels in the tumour decrease, whereas
topoisomerase II mRNA and protein levels rise, after treatment
with camptothecins (Eder et al, 1998) and topotecan (Liebes et al,
1998). The reverse effect, a fall in topoisomerase II and concurrent
rise in topoisomerase I levels with a topoisomerase II-active drug
treatment, is observed, with the suggestion that sequentially
combined topoisomerase I and II agents may result in greater
than additive tumour cytotoxicity with relatively little increase in
toxicity. In vitro studies suggest topoisomerase IIa is cell cycle
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sphase dependent, being only present in the S phase and G2–M
phases of the cell cycle in contrast to topoisomerases I and IIb,
which are expressed constitutively throughout the cell cycle (Heck
and Earnshaw, 1986; Liu, 1989). Agents interacting with any
topoisomerase exhibit cell cycle cytotoxic specificity. However,
there is considerable variation, dependent on dose and schedule,
with notable differences between in vitro and in vivo observations
(Kaufmann, 1991).
The first clinical trials combining topoisomerase I and II
inhibitors have shown substantial, albeit nonlethal, toxicity (Ando
et al, 1997). These studies have focused on etoposide as the
topoisomerase II active agent and have used the camptothecin
analogue first. Sequential treatment appeared to have synergistic
effects with a suggestion of greater than additive tumour
cytotoxicity and no increase in host toxicity. In Seiden et al’s
study, the alternative combination of doxorubicin and topotecan
was chosen because of in vitro observations that firstly, a sequence
of doxorubicin (4 days) followed by camptothecin (4 days)
produced the greatest tumour growth delay in a murine breast
cancer cell line (450%) with no increase in toxicity and secondly,
changes in topoisomerase I levels recovered more rapidly than
topoisomerase II levels (Eder et al, 1998; Seiden et al, 2002).
A phase I trial of sequentially administered etoposide and
topotecan was therefore constructed on these observations. The
objectives of the study were to determine the dose-limiting
toxicities (DLTs) and MTD of sequential etoposide (days (D)1–
5) and topotecan by 96h CIV (D8–11) q 14 in patients with
refractory solid tumour malignancies.
PATIENTS AND METHODS
Eligibility criteria
The study protocol was reviewed and approved by the Dana
Farber/Partners CancerCare (Boston, MA, USA) Institutional
Review Board. An informed consent document satisfying all
federal and institutional requirements was read by the patients and
signed as a condition of their registration. Patients had
histologically documented metastatic or inoperable malignant
solid tumours, for which there was no known curative or standard
palliative therapy. Performance status was Eastern Cooperative
Oncology Group 0–2. Patients had adequate hepatic, renal and
haematological function determined by a serum glutamate-oxalo-
acetate transaminase o2.5 upper limit of normal, bilirubin
o1.5  upper limit of normal, creatinine clearance 450mlmin
 1,
an ANC 41500ml
 1 and platelets 4150000ml
 1. Patients had to
be more than 3 weeks from last chemotherapy, 2 weeks from
surgery, 6 weeks from nitrosoureas or radiotherapy and could not
have had prior pelvic radiotherapy. Women of childbearing
potential could not be pregnant or lactating and fertile participants
had to practise adequate contraception. Additional inclusion
criteria included age 418 years and having central venous access;
patients had to be capable of taking oral medication with an
anticipated life expectancy in excess of 2 months. Eligibility tests
had to be performed within 21 days of commencing therapy.
Treatment plan
The treatment schema is illustrated in Figure 1. Patients had a
history, physical examination, complete blood count and serum
chemistries (including liver function tests, Mg
2þ and creatinine)
performed before each week of therapy, and complete blood count
with differential was performed twice each week. These assess-
ments were repeated at 1 month after the last course of treatment
and on apparent progression. Documentation of all measurable
disease by examination and any appropriate imaging studies (e.g.
plain radiograph, computerised tomography and nuclear medicine
scan) and EKG were performed before therapy, at week 7 and 13.
On weeks 1, 3, 5, 7, 9 and 11, etoposide was administered orally
per allocated dose level (DL) as 10 doses in 5 days with b.i.d.
dosing using the i.v. preparation in sterile prefilled syringes. The
i.v. preparation of etoposide was used instead of the 50mg softgel
capsules (VePesid
s), to allow the necessary dose increments
required for the study. Patients were instructed to squirt the
contents of a syringe into orange juice and drink it, and store the
etoposide at room temperature. On weeks 2, 4, 6, 8, 10 and 12,
topotecan was administered by 96-h i.v. infusion as per allocated
DL. The 96-h i.v. infusion was chosen to allow ambulatory
administration of chemotherapy rather than attending for the
standard D1–5 30-min infusions of chemotherapy. Growth factors
were not allowed to maintain dose intensity. Etoposide (VePesidt;
Bristol-Myers Squibb, Princeton, NJ, USA) and topotecan
(Hycamptint; Smith Kline Beecham, King of Prussia, PA, USA)
were prepared from commercially available supplies, formulated
and administered per institutional guidelines. Antiemetic therapy
could include prn lorazepam 0.5–2.0mg i.v. and/or prochlorper-
azine 10mg p.o. or perphenazine 4mg p.o. as per institutional
standards. The administration of glucocorticoids or 5HT3 anta-
gonists as antiemetics was permitted only after the failure of other
antiemetic agents. All patients were treated with warfarin 1mg p.o.
as prophylaxis against line-related thrombosis unless fully antic-
oagulated for another indication.
Initial DL was 15mgm
 2 b.i.d. etoposide D1–5 with topotecan
D8–12 at 0.2mgm
 2day
 1 q 14. Etoposide was then increased in
subsequent DLs in increments of 5mgm
 2dose
 1 and topotecan
was increased to 0.3mgm
 2day
 1 for DL 2 and then in
0.05mgm
 2day
 1 increments. Initially, three patients fully evalu-
able were to be recruited to DL 1. If there was no DLT, then accrual
continued until the MTD was defined. Dose-limiting toxicities were
defined as Gr III neutropenia for 472h, Gr III thrombocytopenia
and Gr III nonhaematological toxicity by CTC 2.0 criteria.
Subsequent cohorts of patients were accrued if DLT was not
M T W Th F S Su M T W Th F S Su
    Etoposide p.o. b.i.d.       Topotecan i.v. over 96 h 
Dose levels    Etoposide  Topotecan 
Dose level 1    15 mg m–2 b.i.d.   0.2   mg m–2 day–1
Dose level 2    20 mg m–2 b.i.d. 0.3   mg m–2 day–1
Dose level 3    25 mg m–2 b.i.d. 0.35 mg m–2 day–1
Dose level 4    30 mg m–2 b.i.d. 0.4   mg m–2 day–1
Dose level 5    35 mg m–2 b.i.d. 0.45 mg m–2 day–1
Dose level 6    40 mg m–2 b.i.d. 0.5   mg m–2 day–1
Q14 days
Figure 1 Treatment schema. Legend: M, Monday; T, Tuesday; W, Wednesday; Th, Thursday; F, Friday; S, Saturday and S, Sunday. Etoposide administered
orally as the i.v. preparation.
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sobserved in preceding patients over the first 4 weeks of treatment.
If DLT was observed, two further patients were enrolled to that DL
and the occurrence of a second DLT in 2–6 patients established
the previous dose as the MTD. In total, 10 additional patients were
treated at the MTD to better define the profile of toxicity at this
dose.
Dose modifications were not allowed during the first four weeks
of therapy, during which time DLT was evaluated. After week 4,
dose modifications were allowed and based on the neutrophil
and platelet counts on the first and the fourth day of each treat-
ment week. If the ANC was o1000ml
 1 or platelet count was
o100000ml
 1 on D1, no treatment was given that week and a 25%
dose reduction was required for either drug if the ANC was 1000–
1499ml
 1 or platelet count was 100000–149999ml
 1. Treatment
was stopped on D4 of each week of treatment if the ANC was
o1499ml
 1 or platelet count was o149999ml
 1.
Therefore, as the day 4 counts were available after 7/10 doses of
etoposide and approximately 75/96h of topotecan, discontinuation
of treatment on day 4 constituted a total dose reduction for that
cycle of approximately 44%. Patients requiring more than one dose
reduction for a given drug were removed from the study. For the
10 additional patients treated at the MTD, dose reductions were
allowed during the first 4 weeks of treatment at the discretion of
the treating physician. There were no planned dose escalations.
Disease response criteria
For disease measurable radiologically or by examination, response
to therapy was defined in the following manner by standard WHO
criteria. A complete response required the disappearance of all
measurable disease. For patients with ovarian cancer, a serum CA-
125 concentration o35Ul
 1 for a minimum of 30 days was also
required. Partial response was a reduction in tumour burden of
50% or greater for a minimum of 30 days and decrease in serum
CA-125 by at least 50% for patients with an elevated marker.
Progressive disease was indicated by a greater than 25% increase in
tumour burden or serum tumour marker or the appearance of any
new lesion. Stable disease was defined as a decrease in tumour
burden or serum tumour marker level not meeting partial response
criteria or an increase that did not constitute progressive disease.
The following definitions were employed in situations where
disease could not be measured by radiological techniques. A
complete response required normalisation of tumour marker and
complete resolution of evaluable disease such as pleural fluid or
ascites, if present. Partial response was a greater than 50% decrease
in serum tumour marker, with a reduction in ascites or pleural
effusion. A confirmed rising serum tumour marker, even without
confirmation by radiological or physical examination, was
considered progressive disease.
RESULTS
Between October, 1999 and August, 2002, 36 patients were
enrolled. A total of 287 weeks of chemotherapy were delivered
(median 8 (2–19) weeks).
Patient characteristics
The characteristics of the 36 patients enrolled into the study are
summarised in Table 1. The median age was 57 years (range, 22–
78). All patients were evaluable for toxicity. In all, 27 patients had
ovarian cancer, four had sarcoma, three had non-small-cell lung
cancer and one each had thymoma and cholangiocarcinoma.
All patients had progression of tumour with at least one prior
chemotherapy regimen, and 16 patients had received more than
two prior chemotherapy regimens. Only two patients had ECOG
performance score 2.
Additional patients were enrolled to DLs 1 and 2 to replace
patients who developed rapid disease progression. One patient
developed small bowel obstruction at week 3, one patient
developed symptomatic progression of brain metastases at week
3. At DL 4, the study seemed to be near defining the MTD with
haematologic toxicity-triggered dose reductions. However, these
prevented significant toxicity and the protocol was revised to
mandate no dose reductions during the first 4 weeks of therapy.
Despite this, DL 4 appeared tolerable and the dose was escalated
after a total of nine patients had been enrolled at this DL.
Toxicity
Haematologic and nonhaematologic toxicity are recorded in
Tables 1–3. Grade 4 haematologic toxicity did not occur, despite
continual chemotherapy, effectively prevented by the dose delay
and reduction rules. No patient required hospitalisation or
antibiotics for neutropenia and there was no febrile neutropenia.
Significant nonhaematological toxicity was relatively infrequent.
Mild alopecia was common. Six patients experienced mild (one
grade 2) infusion catheter-related discomfort or swelling. One
patient had a problematic paraneoplastic plexopathy, making
evaluation of line-related symptoms difficult, and two patients
developed catheter-related infection, both managed conservatively
with outpatient oral antibiotic therapy with preservation of the
line. Only one catheter-related thrombosis was documented.
Although mucositis was notably rare, an unpleasant metallic taste
was prominent during treatment with etoposide. At DL 6,
continuous nausea, vomiting and fatigue were intolerable. One
patient with primary peritoneal cancer and a past history of
endometrial cancer subsequently developed AML with normal
cytogenetics.
Tumour response
A total of 34 patients were evaluable for response (Table 4). Two
were inevaluable because of the interval development of small
bowel obstruction and cerebral metastases, after 2 and 3 weeks of
therapy, respectively. Overall, six of 34 patients’ (18%) tumours
demonstrated a response, all but one of which were confirmed













Ovarian cancer 27 (75%)
Sarcoma 4 (11%)
Non-small-cell lung cancer 3 (8%)
Thymoma 1 (3%)
Cholangiocarcinoma 1 (3%)
Prior chemotherapy regimens (n)
Median 2
Range 1–6
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s1 month later on imaging, and one of which was a complete
response. The duration of response was a median 8.1 months
(range 6.8–21.5 months). Tumours in many patients developed
minor responses and a response or stable disease was observed
in 56% of patients. All of the tumour responses were observed in
patients with ovarian cancer, for an overall response rate of 23% in
this subgroup. Of the evaluable patients with ovarian cancer, nine
(35%) had been treated with three or more prior lines of therapy.
DISCUSSION
The recent availability of an increasing number of promising
investigational and newly approved drugs has rechallenged the
role of multiagent chemotherapy in the clinical management of
solid tumours with greater impetus for rational combinations
of chemotherapy that maximise efficacy with minimal toxicity
(Cannistra, 2002). However, the best approach for combining
topotecan with other anticancer agents has been debated because
additive myelosuppresssion can markedly limit the doses of drugs
that can be safely administered together (Cannistra, 1999).
Etoposide and topotecan are both commonly used agents with
potential synergy. This study demonstrates that oral etoposide
35mgm
 2 b.i.d. D1–5 and 1.8mgm
 2 96h (total dose) infusional
topotecan can be administered on an alternating continual weekly
schedule for at least 12 weeks, with promising clinical activity.
Furthermore, this potentially maximises the benefit of alternating
induction of topoisomerase I and II. The regimen was found to be
a well tolerated, although a relatively inconvenient, outpatient
treatment. Toxicity is characterised by neutropenia, and thrombo-
cytopenia was dose-limiting with nonhaematological toxicity being
notably mild.
DNA topoisomerases I and IIa are targets for many clinically
important antineoplastic agents. The drugs that interact with
topoisomerase I, the camptothecins, are structurally distinct from
the topoisomerase II-interacting agents of the anthracycline,
epipodophyllotoxin and anthracenedione classes. No clinically
useful agent that preferentially targets topoisomerase IIb has been
developed to date. Maximising the utility of topoisomerase-
interacting agents, by sequential combination, may also minimise
the development of resistance (Potmesil et al, 1988; Sugimoto et al,
1990). Although p-glycoprotein overexpression is likely the most
important, other mechanisms probably also contribute, and
continual, rather than intermittent exposure may limit the
development of resistance (Schneider et al, 1994). Continual
exposure will also limit the development of resistance. However,
whether significant benefit comes from a greater total dose, longer
exposure of a greater number of cycling cells or time above a
concentration threshold is unclear (Joel, 1996).
The rationale for choice of DLs appears to have been justified
by the results. Protracted oral etoposide dose in combination
treatment is typically dosed at 50–75mgm
 2day
 1 (Hainsworth,
1999). There is limited data on topotecan by protracted infusion
in combination regimens. Hochster et al reported an MTD of
0.4mgm
 2day
 1 D1–14 q 21 in combination with short infusion
paclitaxel (Chachoua et al, 1997) and we defined an MTD for
topotecan of 0.7mgm
 2day
 1 by 96h infusion in combination
with 96h infusion paclitaxel (Penson et al, 2001). Doxorubicin and
topotecan administered sequentially could be combined at 60–
70% of the typical dose (Seiden et al, 2002). With the protocol
design calling for protracted sequential treatment without a pause
to allow for recovery of bone marrow function, the starting doses
were reduced a further 50%. The dose reduction strategy set
stringent thresholds for continued treatment in an attempt to
prevent severe myelosuppression. Given the variable and unpre-
dictable bioavailability of oral etoposide, and the resulting variable
tolerability, there was surprisingly little intrapatient variability in
haematological and nonhaematological toxicity during the study.
However, on three occasions, the DL cohorts had to be modified to
accrue more patients.
Table 2 Frequency of worst grade of haematological toxicity
Doses # occurrences of toxicity (grade 1/2/3/4)
DL Etoposide (mgm
 2dose
 1) Topotecan (mgm
 2day
 1) # patients Anaemia Neutropenia Thrombocytopenia
1 15 0.2 4 2/2/0/0 1/1/0/0 0/0/0/0
2 20 0.3 4 0/1/0/0 1/0/0/0 0/0/0/0
3 25 0.35 3 1/2/0/0 0/2/1/0 2/0/0/0
4 30 0.4 9 2/4/1/0 3/3/0/0 1/1/0/0
5 35 0.45 3 1/1/0/0 0/1/0/0 0/1/0/0
6 40 0.5 3 1/3/0/0 0/1/1/0 1/0/0/0
MTD 35 0.45 10 3/6/1/0 1/3/4/0 1/2/0/0
DL¼dose level; MTD¼maximum-tolerated dose.
Table 3 Frequency of worst grade of non-haematological toxicity
# occurrences of toxicity (grade 1/2/3/4)
DL # patients Fatigue Nausea Vomiting Diarrhea Mucositis
1 4 1/2/0/0 1/1/0/0 0/1/1/0 0/2/0/0 0/0/0/0
2 4 3/1/0/0 3/0/0/0 2/0/0/0 0/0/0/0 0/0/0/0
3 3 1/2/0/0 1/2/0/0 2/1/0/0 2/1/0/0 1/0/0/0
4 9 2/4/2/0 3/6/0/0 1/3/0/0 3/3/1/0 0/0/0/0
5 3 2/1/0/0 2/1/0/0 1/0/0/0 0/2/0/0 0/0/0/0
6 3 1/3/0/0 2/1/1/0 1/1/1/0 1/1/0/0 1/0/0/0
MTD 10 2/5/3/0 5/4/1/0 3/1/0/0 1/1/0/0 2/0/0/0
DL¼dose level; MTD¼maximum-tolerated dose.
Table 4 Response to therapy
Characteristic Value (%)
Outcome
Complete response 1 (3%)
Partial response 5 (15%)
Stable disease 14 (41%)
Progressive disease 15 (44%)
Not evaluable 2 (6%)
Overall response rate % (95% CI) 18 (6–31%)
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sTopotecan appears to be a schedule-dependent cytotoxic
(Rowinsky et al, 1992). Phase I and II clinical trials have been
performed to evaluate the administration of topotecan by
continuous i.v. infusion for periods of 24h (van Warmerdam
et al, 1995; Abbruzzese et al, 1996; Hoskins et al, 1998), 72h
(Burris et al, 1994), 120h (Burris et al, 1994) and 21 days
(Hochster et al, 1994). The Canadian National Cancer Institute
conducted a randomised phase II trial to investigate the schedule
dependence of topotecan (Hoskins et al, 1998). Patients received
topotecan given according to the approved dosing regimen,
1.5mgm
 2 i.v. over 30min on 5 consecutive days every 21 days,
or by 24-h i.v. infusion of a 1.75mgm
 2 dose once a week for 4
weeks, with cycles repeated every 6 weeks. The results revealed that
the response rate for topotecan given by the D1–5 dosing regimen
was significantly better than the 24-h infusion schedule (22.6 vs
3.1%, P¼0.026). The weekly 24-h infusion schedule was clearly
associated with less severe haematological toxicity than the
approved dosing regimen. However, the investigators did not
believe that the dose, which had been previously defined in a phase
I study (Haas et al, 1994), could be significantly increased. In
contrast, there are more encouraging results from studies of
topotecan delivered by protracted infusion, in combination with
other chemotherapeutic agents (Hochster et al, 1994), and our own
experience with 96h infusion topotecan has been very positive
(Penson et al, 2001).
While the hope has been to exploit a therapeutic window,
combining topoisomerase I and II inhibitors has been associated
with substantial toxicity. Studies have, in fact, not infrequently
defined an MTD lower than the initial DL (Karato et al, 1993; Ando
et al, 1997). The commonest combinations have been irinotecan
given concurrently with etoposide (Karato et al, 1993; Masuda
et al, 1994; Oshita et al, 1997; Masuda et al, 1998), in which
the DLTs were typically neutropenia and diarrhoea, and required
G-CSF support. A study of sequential irinotecan followed by
etoposide reported a similar MTD (Ando et al, 1997). Other
sequential studies have investigated topotecan and etoposide
(Herben et al, 1997; Hammond et al, 1998) or doxorubicin and
topotecan (Tolcher et al, 1997; Seiden et al, 2002). This study
reports a particularly favourable toxicity profile, with encouraging
efficacy. Although oral etoposide potentially offers a superior
schedule of dosing (Slevin et al, 1989), this has been questioned
(Girling, 1996). Limited data is available about oral topotecan.
However, oral topotecan, or an alternate bioavailable camptothecin
analogue, would obviate the logistical challenges of infusional
chemotherapy and this option is an obvious avenue of investiga-
tion and is being discussed.
In a heavily pretreated population of patients, the response rate
was impressive. There were six radiologically confirmed responses
(18%), three of which were confirmed complete radiological
remissions. The majority (56%) of patients had a tumour response
or stable disease, typically tolerated with minimally toxic
treatment. Although little more than a proof of principle, the
approach of delivering minimally toxic treatment to ‘hold the
disease at bay’, or ‘shrink’ the disease may have delivered blood
concentrations above the therapeutic threshold but below those
associated with significant toxicity. However, this therapeutic
window is far from defined, and is complex given the attempt to
concurrently escalate both drugs.
In summary, this study has demonstrated that oral
etoposide 35mgm
 2 b.i.d. D1–5 and 1.8mgm
 2 96h (total dose)
infusional topotecan can be administered on an alternating
continual weekly schedule for at least 12 weeks with promising
clinical activity that merits a phase II study in patients with
ovarian cancer.
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